Alliances
The agreement with Merck brings $290 million upfront to Orion to access the latter’s investigational candidate, ODM-208, for mCPRC and other related drugs.
Gossamer Bio sold shares of its common stock to pave its runway through mid-2024 while Teva and AbbVie reach deals in opioid settlements.
In what seems like an unlikely collaboration, Seattle-based Fred Hutchinson Cancer Center (Fred Hutch) is partnering with Amazon to develop cancer vaccines.
Backed by biopharma royalty, Areteia Therapeutics will focus on developing an old molecule for a very prevalent disease - asthma.
Genentech has exercised the second option in its potentially $1.7 billion agreement with Bicycle Therapeutics, triggering a $10 million payment.
The experimental drug, being developed to treat immunoglobulin A nephropathy, is IONIS-FB-L Rx, which hit the mark in a Phase II study showing a change in urinary protein after 29 weeks of treatment.
Sanofi announced positive data for its therapeutic, fitusiran, for treating patients with hemophilia A and B, as well as efanesoctocog alfa therapy for treating hemophilia A.
In a filing with the SEC, Abbvie’s decision to terminate came after the two firms jointly conducted a review of their next steps for the drug.
BioSpace caught up with Roland and Ben Buelow of Ancora, and Lightspeed Venture Partners’ Galym Imanbayev to talk about the AstraZeneca deal and the company’s unique business model.
Mogrify and Astellas have forged a collaboration surrounding in vivo regenerative medicine approaches, while CardiNor inked a distribution deal with IBL-America.
PRESS RELEASES